key: cord-0031515-zo2kdv4j authors: O’Donnell, Adrienne; Pham, Nathan; Battisti, Leandra; Epstein, Rachel; Nunes, David; Sawinski, Deirdre; Lodi, Sara title: Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection date: 2022-05-13 journal: PLoS One DOI: 10.1371/journal.pone.0268478 sha: 24ed5f430e769f5108359af7ecb995d5d201daca doc_id: 31515 cord_uid: zo2kdv4j BACKGROUND: Direct-acting antivirals (DAA) are highly effective at treating Hepatitis C virus (HCV) infection, with a cure rate >95%. However, the effect of DAAs on kidney function remains debated. METHODS: We analyzed electronic health record data for DAA-naive patients with chronic HCV infection engaged in HCV care at Boston Medical Center between 2014 and 2018. We compared the following hypothetical interventions using causal inference methods: 1) initiation of DAA and 2) no DAA initiation. For patients with normal kidney function at baseline (eGFR>90 ml/min/1.73m(2)), we estimated and compared the risk for reaching Stage 3 chronic kidney disease (CKD) (eGFR≤60 ml/min/1.73m(2)) under each intervention. For patients with baseline CKD Stages 2–4 (1590 ml/min/1.73m 2 . In Trial 2 we included patients with CKD Stage 2-4 at baseline, defined as eGFR between 15 and 90 ml/min/1.73m 2 . The target trials were identical in all components except for the baseline eGFR inclusion criteria and the outcome definition. We then designed two cohort studies to emulate the protocols of each target trial. S1 and S2 Tables detail the target trials and trial emulations. Eligible individuals met the following criteria between January 2014 and December 2018: age �18 years, chronic HCV infection as described above, no history of kidney transplant or ESRD (defined as CKD Stage 5 or on dialysis), and the presence of a serum creatinine (to compute the baseline eGFR), transaminase, and the platelet measurements within three months of each other (to calculate a Fibrosis-4 [FIB-4] score). In addition, to capture the patients actively engaged in HCV care, we restricted eligibility to individuals with an outpatient visit for HCV infection within three months of their identified HCV infection in the EHR. Individuals who met these eligibility criteria were split into cohort 1 and cohort 2 according to their baseline eGFR and they were analyzed separately. A flow chart of these samples is presented in Fig 1. For both cohorts we compared the following two DAA initiation strategies: 1) initiation of DAA within 3 months of baseline and 2) no DAA initiation. S3 Table details the DAA therapies utilized. The outcome definitions differed by cohort. The outcome for cohort 1 (individuals with normal kidney function) was the development of Stage 3 CKD, defined as the first recorded eGFR�60 ml/min/1.73m 2 . The outcome for cohort 2 (individuals with baseline CKD Stage 2-4) was change from baseline eGFR to the last recorded eGFR between 24-and 30-months post-baseline. For both cohorts, follow-up started at baseline, defined as the earliest date all eligibility criteria were met, and ended at the earliest of one of the following events: death, kidney transplant, ESRD (defined as CKD Stage 5 or on dialysis), 2 years post-baseline, administrative end of follow-up (December 2018), or, in Trial 1, date of outcome. A summary of the study design is presented in Fig 2 [29] . We summarized the baseline characteristics of each cohort separately using descriptive statistics. For cohort 1, we used a time-to-event framework to estimate and compare the 2-year cumulative incidence of reaching Stage 3 CKD under the two DAA initiation strategies. For cohort 2, we estimated and compared the mean 2-year change from baseline eGFR under each intervention. Because standard statistical methods cannot appropriately adjust for time-varying confounding, we used the parametric g-formula to generate adjusted estimates [30] [31] [32] . Covariates were chosen a priori based on the co-authors' clinical judgement and review of the published literature. Like all causal inference methods, the parametric g-formula estimates the causal effect of a hypothetical intervention (here, the DAA therapy initiation) under the identifiability assumptions (positivity, exchangeability, and consistency) and assumes a correct model specification [30] . The parametric g-formula algorithm has been described in detail elsewhere [33] [34] [35] . Briefly, it works in two steps: 1) parametric regression models estimate the joint distribution of the outcome, treatment, and time-varying covariates conditional on previous treatment and covariate history and 2) the estimates in step 1 are used to simulate the distribution of the outcome under each intervention using the Monte Carlo method. In the first step, continuous and binary time-varying covariates were modeled with separate linear and logistic regression models, respectively. All models adjusted for baseline covariates and the most recent lagged value of time-varying covariates. Baseline covariates included age, sex, race/ethnicity (Hispanic or Latino, White, Black, other), body mass index, education level, HCV genotype, insurance type, degree of liver fibrosis (by fibroscan), HIV coinfection, and diabetes. Time-varying covariates were alanine transaminase (ALT), aspartate transaminase (AST), platelet count, change from baseline eGFR, drug or alcohol use disorder [36] , mental illness, outpatient visits, and hypertension. We also treated the timing of the laboratory measurements (AST, ALT, platelet count, eGFR) as potential confounders: we fit logistic regression models for these visit processes with a binary outcome of 1 if a measurement was taken at that time and 0 if not. For cohort 1, continuous eGFR was included as an additional baseline covariate, and for cohort 2 CKD stage was included as an additional baseline covariate. Skewed continuous covariates (ALT and AST) were log-transformed for normality. Details on the definition and ascertainment of covariates are presented in S4 Table. In the second step, we used the parameter estimates from the first step to simulate the postbaseline time-varying covariates and the outcome separately under each of the two interventions. In our real-world data, eGFR is measured sporadically and long periods of time can elapse between measurements. Therefore, we imposed an eGFR measurement after 12 months in individuals without a new measurement. We used nonparametric bootstrapping with 500 samples to obtain 95% confidence intervals (CI) around our estimates based on percentiles. To explore the validity of our parametric assumptions, we compared the observed outcome means and time-varying covariates with those predicted by our models (S3 and S4 Figs) . All analyses were conducted in SAS version 9.4 using the publicly available GFORMULA macro [37] . As secondary analyses, we reran the estimation procedure in the following patient subgroups with elevated risk of CKD [38] : those with 1) type II Diabetes, 2) hypertension, and 3) age>45 years. The cut-off for age was chosen according to the bimodality of the distribution of age in the study sample (S5 Fig). We conducted several sensitivity analyses to assess the robustness of our results. First, we reran the analysis for both cohort 1 and cohort 2 excluding HCV and HIV coinfected patients [39] . Second, we reran the analysis for both cohorts restricting them to outpatient eGFR measurements only. This was done to attempt to exclude acute renal injuries. Third, we reran the analysis for cohort 1 with the follow-up extended to the database close (2018), and we reran the analysis for cohort 2 with the follow-up extended to 3 years. Fourth, we conducted the analyses with time discretized into months, instead of weeks as was done in the main analysis. Fifth, we ran a series of analyses reordering the time-varying covariates, since each parametric model conditions on past covariates. Sixth, we reran the analyses by 1) imposing an eGFR measurement after 6 months, instead of 12 months, and 2) not imposing a new eGFR measurement. In addition, for cohort 1, we ran a sensitivity analysis defining Stage 3 CKD as the first of two eGFR measurements <60 ml/min/1.73m 2 to be consistent with the official CKD diagnosis guidelines [23] . We also reran the primary analysis additionally adjusting for concomitant use of nephrotoxic medications (nonsteroidal anti-inflammatory drugs, diuretics, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). Finally, we reran the primary analyses to estimate the effect of treatment with Sofosbuvir-containing regimens on renal function. We did this by censoring patients treated with non-Sofosbuvir-containing regimens at their treatment start date. Descriptive characteristics at baseline for each cohort are presented in Table 1 . Descriptive characteristics stratified by treatment with DAA are presented in S5 In cohort 1, 101 (7%) individuals developed Stage 3 CKD events and 13 died during 3,048 person-years of follow-up. As presented in Table 2 , the adjusted estimated 2-year risk (95% CI) of reaching Stage 3 CKD was 5% (3%, 6%) and 5% (4%, 8%) under DAA initiation and no DAA initiation, respectively (risk difference -1% (-3%, 2%)). Cohort 2 and 435 (59%) were male. At baseline, 68% had hypertension and 26% had diabetes. In cohort 2, 514 (70%) patients initiated DAA during follow-up and of these, 316 (61%) initiated DAA within 3 months of baseline. Among the 514 who initiated DAA, 494 (96%) had a posttreatment HCV-RNA measured, and 481 of 494 (97%) achieved SVR defined as an undetectable HCV-RNA. In cohort 2, the observed mean (standard deviation, SD) change from baseline eGFR was 0 (16) ml/min/1.73m 2 . The adjusted estimated mean (95% CI) change from baseline in eGFR was 0 (-3, 2) ml/min/1.73m 2 and 3 (-1, 8) ml/min/1.73m 2 under DAA initiation and no DAA initiation, respectively. Compared to no DAA initiation, the mean difference was -3 (-8, 2) ml/ min/1.73m 2 under DAA initiation. There were 14 deaths during the follow-up in cohort 2. Results of subgroup analyses are presented in S6-S8 Tables. Individuals with diabetes, with hypertension, or aged >45 years had a higher incidence of CKD Stage 3 (cohort 1) and a faster eGFR decline (cohort 2) at 2 years post-baseline compared to their counterparts without diabetes, without hypertension, or aged �45 years. Effect estimates were similar to those in the main analysis, although with lower precision due to smaller sample sizes. The subgroup of patients aged �45 years in cohort 2 had too few patients (N = 78) to allow for estimation. Results from sensitivity analyses were consistent with main results for both cohorts (S6 and S7 Figs). The distribution of the time-varying means predicted by our models were similar to the observed means (S3 and S4 Figs). We estimated the causal effect of initiating versus not initiating DAA treatment on kidney function in two cohorts of patients with HCV infection: one with normal kidney function (cohort 1) and one with baseline CKD Stage 2-4 (cohort 2). For those with normal kidney function at baseline, we observed no difference in the risk of reaching Stage 3 CKD had all patients initiated DAA therapy versus had all patients not initiated DAA therapy. Similarly, for those with CKD Stage 2-4 at baseline, we observed no difference in 2-year post-baseline change in eGFR had all versus no patients initiated DAA. These results were robust to several sensitivity analyses that varied analytic decisions and model specification. Additionally, in our secondary analysis we evaluated patient subgroups which might particularly benefit from treatment and found no effect of DAAs on renal function. Altogether these findings suggest that treatment with DAA for HCV infection neither impairs nor improves renal function over a 2-year period. Previous observational studies estimated the association between DAA treatment and eGFR trends. Specifically, Driedger et al. reported no notable change in renal function before and after DAA initiation [17] . In another study, Medeiros et al. found no association between sofosbuvir-based DAA regimens and eGFR among a group of patients with baseline eGFR<45 ml/min/1.73m 2 , but observed improvements in renal function among those with eGFR>45 ml/min/1.73m 2 [18] . An observational study by Sise et al. compared eGFR slope one year before and one year after DAA initiation and found no difference among those with baseline eGFR>60 ml/min/1.73m 2 but reported improvements among those with baseline eGFR<60 ml/min/1.73m 2 [16] . In addition, in a retrospective cohort study of patients treated with ledipasvir/sofosbuvir for HCV genotype 1b, Okubo et al. reported no changes in eGFR from pretreatment to 12 weeks post-treatment among those with CKD Stage 3 [10] . Finally, a prospective observational study with biannual eGFR measurements found no significant difference in eGFR evolution among DAA-treated individuals who did and did not achieve SVR [19] . All these studies compared kidney function before and after DAA treatment, therefore, they were only analyzing patients who received DAA treatment. While this approach allows for control of baseline confounding factors, whereby patients act as their own controls, these estimates might be biased if patients who received DAA treatment had worse (or better) renal function than those who did not [9, 40, 41] . In contrast, we designed our study to include all patients eligible to receive DAA treatment and we adjusted for potential confounders. Despite a different study design, our results are not only consistent with the lack of a clear association between treatment with DAAs and renal function in the literature, but also are generalizable to all patients eligible to receive DAAs. Our study has important strengths. We used longitudinal data from an urban safety net hospital with a notable HCV testing and screening program, which allowed us to include a diverse patient population. We analyzed this rich source of real-world data with causal inference methods that explicitly adjusted for time-varying confounding and selection bias. Timevarying confounding is intrinsic to this study setting: elevated liver function tests and the presence of certain covariates indicate a more pressing need for treatment, and treatment improves liver function [12, 13] . Selection bias is also present, whereby patients with CKD at baseline have more frequent post-baseline eGFR measurements than individuals with normal renal function [32] . We address both methodological issues by adjusting for variables associated with renal function, including explicit adjustment for renal monitoring frequency. By stratifying patients into cohorts according to baseline renal function, we aimed to reduce the impact of selection bias on our results. Our study explicitly estimated what would have happened had all patients initiated versus not initiated DAA, which differs from, but complements, previous studies that compared renal function before and after DAA therapy. As it would be unethical to conduct a randomized controlled trial (RCT) that assigns some patients to HCV treatment and others not, our study is as close methodologically as possible to an RCT and, notably, enables us to comment upon causation, not merely association. Our study also has several limitations. First, our methods rely on the assumption of no residual confounding, yet we may not have captured all confounding characteristics. However, we separately analyzed two cohorts with different baseline renal function and clinical and demographic characteristics, and, thus, likely they also had different confounding structures. We found the null effect in both cohorts, therefore, it reinforced our conclusions. Second, retrospective use of EHRs is subject to error: we may have missed deaths, HCV treatments, or laboratory measurements done outside the hospital system. Third, we used prescriptions to ascertain DAA treatment initiation, but we had no record of medication adherence. Treatment completion rates for DAAs as low as 68% have been reported for HCV infected patients [11] . However, a recent study in an overlapping sub-population at Boston Medical Center found, by comparing chart-reviewed DAA adherence with EHR prescription records, that only 7% of individuals prescribed DAAs never started treatment [42] . Fourth, because of the relatively high eGFR in our sample, we used a baseline eGFR cutoff of 90 ml/min/1.73m 2 . The cutoff for clinically significant CKD is 60 ml/min/1.73m 2 , and so future studies with larger sample size and/or more renally impaired patients should replicate this research with the more stringent cutoff [21] . Finally, the majority of individuals who initiated DAA treatment received sofosbuvir-containing regimens, in line with DAA treatment in the United States during the study period. A future study with a larger database, perhaps pooling data across medical centers, may look at the effect of specific DAA combinations on renal function [20] . Despite these limitations, our results have important implications for renal monitoring among patients treated with DAA. Frequency of renal monitoring should remain the same after treatment with DAA as it was before for those with and without renal impairment. According to Kidney Disease: Improving Global Outcomes guidelines, this means at least annual eGFR monitoring for those with normal renal function and 1 to 4+ times per year for those with CKD, depending on severity [21] . Our study suggests DAAs may not be nephrotoxic and that HCV clearance may not restore renal function, but future research should continue to work to elucidate these relationships. In conclusion, we used robust methodology combined with a rich source of data and found no causal effect of DAA treatment on kidney function. Hepatitis C and kidney disease: A narrative review Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans Facts Negro F. and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection Association of hepatitis C virus infection with risk of ESRD: A population-based study Hepatitis C virus infection increases risk of developing end-stage renal disease using competing risk analysis Center for Drug Evaluation and Research. Chronic hepatitis C virus infection: Developing direct-acting antiviral drugs for treatment guidance for industry Access to costly new hepatitis C drugs: Medicine, money, and advocacy Efficacy and safety of ledipasvir/ sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis Extrahepatic manifestations of chronic HCV infection Direct-acting antiviral therapy slows kidney function decline in patients with hepatitis C virus infection and chronic kidney disease Direct acting antiviral HCV treatment does not influence renal function Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study Long-term Evolution of Estimated Glomerular Filtration Rate in Patients With Antiviral Treatment for Hepatitis C Virus Infection Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals Kidney disease: Improving global outcomes hepatitis C working group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation and treatment of hepatitis C in chronic kidney disease Ribavirin: Past, present and future Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function Using big data to emulate a target trial when a randomized trial is not available HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center Impact of the 2020 COVID-19 pandemic on ambulatory hepatitis C testing A new equation to estimate glomerular filtration rate Methods of estimating GFR-different equations including CKD-EPI Graphical depiction of longitudinal study designs in health care databases A new approach to causal inference in mortality studies with a sustained exposure periodapplication to control of the healthy worker survivor effect Estimation of the causal effects of time-varying exposures A structural approach to selection bias Comparative effectiveness of dynamic treatment regimes: An application of the parametric g-formula Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: Observational cohort study Intervening on risk factors for coronary heart disease: An application of the parametric g-formula Identifying injection drug use and estimating population size of people who inject drugs using healthcare administrative datasets GFORMULA 3.0 -the parametric gformula in SAS Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function Hepatic decompensation in antiretroviraltreated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: A cohort study Simple, effective, but out of reach? public health implications of HCV drugs Adoption of direct-acting antiviral medications for hepatitis C: A retrospective observational study Enhancing linkage to hepatitis C virus treatment following pregnancy in women identified during perinatal care We thank the patients, clinical team, and database managers at Boston Medical Center for providing us with the electronic health records used in this study.